Altropane (Boston Life Science)

Cattabeni, F.

Current Opinion in Investigational Drugs 3(11): 1647-1651

2002


ISSN/ISBN: 1472-4472
PMID: 12476968
Document Number: 544817
Boston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and attention deficit hyperactivity disorder (ADHD) [329661]. Altropane is currently in phase III clinical trials for PD and phase II clinical trials for ADHD.

Document emailed within 1 workday
Secure & encrypted payments